IP Library Granted Patent US 10,889,550
Granted Patent B2
US 10,889,550 · App. 16/143,748 · Granted Jan 12, 2021

Contrast agents for myocardial perfusion imaging

Inventors: David S. Casebier (Carlisle, MA); Simon P. Robinson (Stow, MA); Ajay Purohit (Sudbury, MA); Heike S. Radeke (South Grafton, MA); Michael T. Azure (Renlop, AL); Douglas D. Dischino (Middlefield, CT)
Assignee: Lantheus Medical Imaging, Inc.
C07D237/16A61K49/00A61K49/0002A61K49/0052A61K49/10A61K49/22A61K51/04A61K51/0421A61K51/0453A61K51/0459C07B59/002C07D239/88
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,889,550
App. No.
16/143,748
Granted
Jan 12, 2021
Kind
B2
Abstract

The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.

Claims (20)

1. A contrast agent comprising an imaging moiety, and a fenazaquin analog having the structure of formula (II),

wherein:

G is

wherein:

R 30 , R 31 , R 32 , and R 3 are independently selected from hydrogen, C 1 -C 6 alkyl optionally substituted with an imaging moiety, and an imaging moiety;

R 34 is selected from hydrogen and an imaging moiety;

J is selected from N(R 27 ), S, O, C(═O), C(═O)O, NHCH 2 CH 2 O, a bond, and C(═O)N(R 27 ), with each group being drawn with its left end attached to G and its right end attached to the carbon substituted with R 21 and R 22 ;

wherein R 27 is selected from hydrogen, C 1 -C 6 alkyl optionally substituted with an imaging moiety, and an imaging moiety;

when present, K is selected from hydrogen, alkoxyalkyl, alkyloxy, aryl, C 1 -C 6 alkyl optionally substituted with an imaging moiety, heteroaryl, and an imaging moiety;

when present, L is selected from hydrogen, alkoxyalkyl, alkyloxy, aryl, C 1 -C 6 alkyl optionally substituted with an imaging moiety, heteroaryl, and an imaging moiety;

M is selected from hydrogen, alkoxyalkyl, alkyloxy, aryl, C 1 -C 6 alkyl optionally substituted with an imaging moiety, heteroaryl, and an imaging moiety; or

L and M, together with the atom to which they are attached, form a three- or four-membered carbocyclic ring;

n is 0, 1, 2, or 3;

Y is selected from a bond, carbon, and oxygen; provided that when Y is a bond, K and L are absent and M is selected from aryl and heteroaryl; and provided that when Y is oxygen, K and L are absent and M is selected from hydrogen, alkoxyalkyl, aryl, C 1 -C 6 alkyl optionally substituted with an imaging moiety, and heteroaryl;

provided that at least one imaging moiety is present in formula (II),

wherein the imaging moiety is 11 C, 13 N, 18 F, 123 I, 125 I, 99m Tc, 95 Tc, 111 In, 62 Cu, 64 Cu, 67 Ga, or 68 Ga.

2. The contrast agent of claim 1 wherein the contrast agent is selected from

3. A method of imaging myocardial perfusion comprising administering to a patient a contrast agent of claim 1 , and scanning the patient using diagnostic imaging.

4. The contrast agent of claim 1 , wherein the imaging moiety is 18 F.

5. The contrast agent of claim 1 , wherein the imaging moiety is 99m Tc.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Dec 2, 2022
From: WELLS FARGO BANK, N.A.
To: LANTHEUS MEDICAL IMAGING, INC.
Reel/Frame 062047/0925 →
SECURITY INTEREST Recorded Dec 2, 2022
From: LANTHEUS MEDICAL IMAGING, INC.; MOLECULAR INSIGHT PHARMACEUTICALS, INC.; PSMA DEVELOPMENT COMPANY, LLC; PROGENICS PHARMACEUTICALS, INC.
To: CITIZENS BANK, N.A.
Reel/Frame 062047/0960 →
NUNC PRO TUNC ASSIGNMENT Recorded Feb 27, 2020
From: BRISTOL-MYERS SQUIBB COMPANY
To: BRISTOL-MYERS SQUIBB PHARMA COMPANY
Reel/Frame 051947/0837 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2020
From: CASEBIER, DAVID S.; ROBINSON, SIMON P.; PUROHIT, AJAY; RADEKE, HEIKE S.; AZURE, MICHAEL T.; DISCHINO, DOUGLAS D.
To: BRISTOL-MYERS SQUIBB PHARMA COMPANY
Reel/Frame 051947/0863 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2020
From: BRISTOL-MYERS SQUIBB PHARMA COMPANY
To: ACP LANTERN ACQUISITION, INC.
Reel/Frame 052043/0887 →
MERGER Recorded Feb 27, 2020
From: ACP LANTERN ACQUISITION, INC.
To: BRISTOL-MYERS SQUIBB MEDICAL IMAGING, INC.
Reel/Frame 052044/0065 →
CHANGE OF NAME Recorded Feb 27, 2020
From: BRISTOL-MYERS SQUIBB MEDICAL IMAGING, INC.
To: LANTHEUS MEDICAL IMAGING, INC.
Reel/Frame 052044/0167 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 27, 2020
From: CASEBIER, DAVID S.; ROBINSON, SIMON P.; PUROHIT, AJAY; RADEKE, HEIKE S.; AZURE, MICHAEL T.; DISCHINO, DOUGLAS D.
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 051947/0811 →
SECURITY AGREEMENT Recorded Jun 28, 2019
From: LANTHEUS MEDICAL IMAGING, INC.
To: WELLS FARGO BANK, N.A.
Reel/Frame 049628/0001 →
Cited By (1)
US 12,527,884